XNASALTS
Market cap76mUSD
Jan 13, Last price
5.69USD
1D
-2.32%
1Q
249.17%
Jan 2017
12.86%
IPO
-78.06%
Name
Janone Inc
Chart & Performance
Profile
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through three segments: Biotechnology, Recycling, and Technology. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs; and designs, develops, and sells cellular transceiver modules and associated wireless services. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2022‑00 | 2021‑00 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2016‑00 | |
Income | |||||||||
Revenues | 39,611 16.96% | ||||||||
Cost of revenue | 1,500 | 31,992 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (1,500) | 7,619 | |||||||
NOPBT Margin | 19.23% | ||||||||
Operating Taxes | (429) | (6,671) | |||||||
Tax Rate | |||||||||
NOPAT | (1,071) | 14,290 | |||||||
Net income | (20,060) 18.79% | 3,589 -142.23% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 1,051 | ||||||||
BB yield | -47.28% | ||||||||
Debt | |||||||||
Debt current | 6,692 | ||||||||
Long-term debt | 707 | 11,208 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 34 | 46 | |||||||
Net debt | 416 | 17,470 | |||||||
Cash flow | |||||||||
Cash from operating activities | 1,463 | (3,056) | |||||||
CAPEX | (1,509) | ||||||||
Cash from investing activities | (155) | (1,509) | |||||||
Cash from financing activities | (1,435) | 3,979 | |||||||
FCF | 1,842 | 9,141 | |||||||
Balance | |||||||||
Cash | 5 | 115 | |||||||
Long term investments | 286 | 315 | |||||||
Excess cash | 291 | ||||||||
Stockholders' equity | (50,631) | (28,931) | |||||||
Invested Capital | 62,574 | 51,759 | |||||||
ROIC | 31.00% | ||||||||
ROCE | 33.09% | ||||||||
EV | |||||||||
Common stock shares outstanding | 4,005 | 3,150 | |||||||
Price | 0.56 -86.43% | 1.37 -71.98% | |||||||
Market cap | 2,223 -79.56% | 4,316 -52.35% | |||||||
EV | 17,149 | 36,296 | |||||||
EBITDA | 8,231 | ||||||||
EV/EBITDA | 4.41 | ||||||||
Interest | 489 | ||||||||
Interest/NOPBT | 6.42% |